LAUSR

comparable for expected response to SARS-CoV-2. Authors cite the work of Breccia et al. to claim that “there is no data suggesting that chronic phase CML patients are at higher risk of infection for SARS-CoV-2 compared to the general population”. Breccia et al. studied CML patients in 2020 and had no experience with SARS-CoV-2. Even if we confirm that CML patients are equally likely with general population to develop COVID-19, we cannot claim similar outcomes and or drug-related responses in either group upon exposure to SARS-CoV-2. More importantly, TKI was not used in CML patients for COVID-19 but rather as an integrated agent of their ongoing therapy. Shortly, we would like to note that the study should be treated as case series of CML patients (using TKI) with confirmed COVID-19, as the title emphasizes. The study has neither an analytical observational nor experimental design to claim an effect of TKI in COVID-19, if any. Currently, COVID-19 has no licensed therapeutics; physicians should be able to critically appraise the emerging evidence on off-label drug use and the quality of evidence supporting it.